Unique ID issued by UMIN | UMIN000036029 |
---|---|
Receipt number | R000041038 |
Scientific Title | A cross-sectional study of health insurance database in Japan: Real-world surveillance for treatment of pediatric gout/ hyperuricemia with urate lowering agents |
Date of disclosure of the study information | 2019/02/27 |
Last modified on | 2019/02/27 16:33:41 |
A cross-sectional study of health insurance database in Japan: Real-world surveillance for treatment of pediatric gout/ hyperuricemia with urate lowering agents
Real-world surveillance for treatment of pediatric gout/asymptomatic hyperuricemia with urate lowering agents
A cross-sectional study of health insurance database in Japan: Real-world surveillance for treatment of pediatric gout/ hyperuricemia with urate lowering agents
Real-world surveillance for treatment of pediatric gout/asymptomatic hyperuricemia with urate lowering agents
Japan |
Gout and Hyperuricemia
Medicine in general | Cardiology | Endocrinology and Metabolism |
Nephrology | Pediatrics |
Others
NO
To reveal the real clinical practice for treatment of pediatric gout/hyperuricemia with urate lowering agents using a health insurance database in Japan
Others
Diagnosis and treatment status
Others
Others
Not applicable
1. Prevalence rate and treatment rate with urate lowering agents for pediatric gout/asymptomatic hyperuricemia patients.
2. Patients' characteristics: patients with diagnosis and/or urate lowering treatment (ULT) in pediatric gout/asymptomatic hyperuricemia.
3. Number of ULT prescribed patients, average dosage, adherence and change of ULT agents
4. Incidence and prevalence of gouty arthritis
Not Applicable
Observational
Not applicable |
18 | years-old | >= |
Male and Female
1. Subjects who are continuously identified in a JMDC Claim Database during the period between April 2016 and March 2017. If necessary, subjects who are identified between April 2012 and March 2016 would be analyzed as well.
2. Patients who have gout or asymptomatic hyperuricemia.
(This criteria is not applied for denominator when calculating diagnosis and treatment rates for gout/hyperuricemia.)
3. Patients ages between 0 and 18 years old.
Patients who have malignancy.
(This criteria is not applied for denominator when calculating diagnosis and treatment rates for gout/hyperuricemia.)
300
1st name | |
Middle name | |
Last name | Hideki Horiuchi, PhD. |
Teijin Pharma Limited
Medical Science Department
2-1, Kasumigaseki 3-Chome, Chiyoda-ku, Tokyo 100-8585, Japan
+81-3-3506-4140
h.horiuchi@teijin.co.jp
1st name | |
Middle name | |
Last name | Tomoko Torii, MSc. |
Teijin Pharma Limited
Medical Science Department
2-1, Kasumigaseki 3-Chome, Chiyoda-ku, Tokyo 100-8585, Japan
+81-3-3506-4140
tpm-com@umin.ac.jp
Teijin Pharma Limited
Teijin Pharma Limited
Self funding
Japan
NO
2019 | Year | 02 | Month | 27 | Day |
Unpublished
Preinitiation
2019 | Year | 01 | Month | 29 | Day |
2019 | Year | 01 | Month | 29 | Day |
This is a cross-sectional study of health insurance database provided by JMDC Inc. in Japan.
2019 | Year | 02 | Month | 27 | Day |
2019 | Year | 02 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041038
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |